Prices delayed by at least 15 minutes | Print
FENNEC PHARMACEUTICALS INC (FRX)
EquityOpen
13.77 CAD
Previous close
14.32 CAD
Trade high
13.77 CAD
Volume
200
Year high
15.43 CAD
Year low
9.27 CAD
Dividend yield
-
Market capitalisation
373.17 mn CAD
P/E ratio
-
ISIN
CA31447P1009
This share can be held in a Dealing accountISALifetime ISAJISASIPP
Share price
Company profile
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.